Research Summary

Analyzed using Evidence Intelligence™

Dapagliflozin shows no long-term harm to bone health in women with diabetes

Key finding

Trabecular thickness was significantly higher in the dapagliflozin group (0.230 ± 0.02 vs 0.218 ± 0.01, p=0.003).

This study investigated the effects of dapagliflozin on bone metabolism in post-menopausal women with type 2 diabetes, finding significant improvements in trabecular and cortical thickness.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Some Concerns bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Dapagliflozin

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Primary outcome

Bone mineral density (BMD) at lumbar spine

Comparator

Standard-of-care alone

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study investigated the effects of dapagliflozin on bone metabolism in post-menopausal women with type 2 diabetes, finding significant improvements in trabecular and cortical thickness.

Clinical relevance

Understanding the impact of dapagliflozin on bone metabolism is crucial for managing the health of post-menopausal women with type 2 diabetes, a group at increased risk for osteoporosis. The findings suggest that dapagliflozin may offer additional benefits beyond glucose control, potentially improving bone health and reducing fracture risk in this population.

Keep in mind

The study did not measure long-term effects on fracture risk. Sample size and demographic characteristics may limit generalizability. The study design does not allow for causal conclusions.

Published in

Journal Reference

Publication details and source links for this paper.

Sanjay KB, Liza D, Mintu B, et al. Effects of Dapagliflozin on Bone Metabolism in Post-Menopausal Women with Type 2 Diabetes. Journal of the Endocrine Society. 2024;8(Suppl 1):bvae163.370. doi:10.1210/jendso/bvae163.370

View DOI View on PMC

Save this study and add notes to your research library.

Main Effects

Trabecular thickness was significantly higher in the dapagliflozin group (0.230 ± 0.02 vs 0.218 ± 0.01, p=0.003).

Cortical thickness was significantly higher in the dapagliflozin group (1.104 ± 0.2 vs 0.998 ± 0.2, p=0.04).

Intra-cortical porosity was significantly higher in the dapagliflozin group (0.008 ± 0.005 vs 0.005 ± 0.003, p=0.020).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Dapagliflozin and Bone mineral density (BMD), Bone mineral density (BMD) at distal radius, Bone mineral density (BMD) at femoral neck, and 7 more.

This study contributes evidence to

Intervention

Dapagliflozin

Outcome

Bone mineral density (BMD)

Evidence topic

Bone Mineral Density

Primary intervention

Dapagliflozin

Primary outcomes

Bone mineral density (BMD)
Bone mineral density (BMD) at distal radius
Bone mineral density (BMD) at femoral neck

Evidence topics

Bone Mineral Density SGLT2 Inhibitors

Primary intervention

Dapagliflozin

Primary outcomes

Bone mineral density (BMD)Bone mineral density (BMD) at distal radius Bone mineral density (BMD) at femoral neck

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 64

Why it is useful

Contributes to 10 evidence relationships
Includes primary outcome data
Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Dapagliflozin → Trabecular thickness (Tb.Th)

Evidence profile

StrongIncreaseClinical Outcomes

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Dapagliflozin improved trabecular thickness by 0.012 cm (p=0.003).
Cortical thickness increased by 0.106 cm with dapagliflozin (p=0.04).
Intra-cortical porosity increased by 0.003 cm (p=0.020).

Who this applies to

Post-menopausal women aged 50 and older.
Individuals diagnosed with type 2 diabetes.

Keep in Mind

Results may not apply to pre-menopausal women or men.
The study's short duration limits understanding of long-term effects.
Further research is needed to explore the clinical significance of findings.

Between the Lines

The study did not measure long-term effects on fracture risk.
Sample size and demographic characteristics may limit generalizability.
The study design does not allow for causal conclusions.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on SGLT2 Inhibitors and Cortical pore diameter (Ct.Po.Dm) at radius, SGLT2 Inhibitors and Cortical pore diameter (Ct.Po.Dm) at tibia.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

SGLT2 InhibitorsCortical pore diameter (Ct.Po.Dm) at radius

Medications

1 studies

Detailed evidence

SGLT2 InhibitorsCortical pore diameter (Ct.Po.Dm) at tibia

Medications

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does SGLT2 Inhibitors improve kidney function?

Emerging Evidence

Current evidence does not show a clear benefit of SGLT2 Inhibitors for Kidney Function.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Serum CTX-1
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors improve bone mineral density?

Limited Evidence

Current evidence does not show a clear benefit of SGLT2 Inhibitors for Bone Mineral Density.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Bone mineral density (BMD)
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Consistent | 1 study
2
Bone mineral density (BMD) at distal radius
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study
3
Bone mineral density (BMD) at femoral neck
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Population details are unavailable.

View Full Evidence

Does Dapagliflozin improve cortical pore diameter (ct.po.dm) at radius?

Emerging Evidence

Dapagliflozin appears to improve Cortical pore diameter (Ct.Po.Dm) at radius.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Cortical pore diameter (Ct.Po.Dm) at radius
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Dapagliflozin improve cortical pore diameter (ct.po.dm) at tibia?

Emerging Evidence

Dapagliflozin appears to improve Cortical pore diameter (Ct.Po.Dm) at tibia.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Cortical pore diameter (Ct.Po.Dm) at tibia
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Bone Mineral Density Evidence Hub SGLT2 Inhibitors Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Dapagliflozin and Bone mineral density (BMD)All studies on Dapagliflozin and Bone mineral density (BMD) at distal radius All studies on Dapagliflozin and Bone mineral density (BMD) at femoral neck All studies on Dapagliflozin and Cortical pore diameter (Ct.Po.Dm) at radius

Related research

Read related research summaries.

Dapagliflozin improves metabolic outcomes in type 2 diabetes patients Dapagliflozin may improve RAAS markers in diabetes patients Dapagliflozin-linagliptin combo improves glycemic control and organ protection Dapagliflozin improves brain function in type 2 diabetes Dapagliflozin reduces IL-1B but does not improve cardiac fibrosis in T2D patients.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.